Praxadine is the anti-inflammatory and analgesic agent. Praxadine inhibited the activity of purified inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS) isoforms to a similar extent.

Omaciclovir (previously known as H2G), a cyclic guanosine analog that is structurally similar to acyclovir and was in clinical development for the treatment of herpesvirus infections. This drug acted against varicella-zoster virus (VZV), by the formation of high concentrations of relatively stable H2G-triphosphate, which is a potent inhibitor of the viral DNA polymerases. However, further development of this drug was discontinued.

Minalrestat was developed by Wyeth-Ayerst as an aldose reductase inhibitor. It is known, the aldose reductase inhibition might ameliorate diabetic complications through the correction of the altered microvascular reactivity by a mechanism that involves NO and membrane hyperpolarization. That is why minalrestat was studied for patients with diabetic retinopathy. However, Wyeth discontinued development of minalrestat.

Tinabinol is a thiopyranobenzopyran derivative patented by Sharps Associates as tranquilizing agent. In preclinical modes Tinabinol shows good analgesic properties and causes ataxia in dogs at low doses.

Lombazole is an antimicrobial agent of the imidazole class. It induced profound ultrastructural changes in Staphylococcus epidermidis and Candida albicans. Like other members of the imidazole series, such as clotrimazole, miconazole, and bifonazole, the compound has a broad spectrum of activity. It is active against several budding and filamentous fungi as well as gram-positive bacteria. Lombazole most probably interferes with fungal lipid synthesis by inhibiting sterol C-14 demethylation. Lipid biosynthesis is the primary site of action of lombazole in the bacterium Staphylococcus epidermidis. Lombazole was recommended against akne.

Nictindole is a non-steroidal anti-inflammatory agent. It is a thromboxane synthetase inhibitor. Nictindole inhibits generation of TXA2 in human platelet rich plasma.

Dabelotine is a cognitive-enhancing drug, developed by Servier. The drug has been shown to improve some aspects of cognitive processes, such as attention, curiosity, motivation, acquisition, and recall of memory. Dabelotine has also been shown to reduce the effect of an anticholinergic drug such as scopolamine. The drug increases the in vitro K+-induced norepinephrine release in rodent cerebral slices, and have no effect on noradrenergic and cholinergic receptor binding sites. Dabelotine was investigated in phase 2 clinical trials for the treatment of dementia, where it was demonstrated that 50-mg and 100-mg doses produced an improvement in reaction time and performance in memory tasks.

Lydimycin is a biosynthetic product obtained by culturing a lydimycin-producing actinomycete in a suitable aqueous nutrient medium under aerobic conditions. Lydimycin inhibits the growth of Nocardia asteroides, Blastomyces dermatitidis, Geotrichum sp., Phlalophora varrucosa, Cryptococcus neoformans, H Histoplasma capsulatum, and Trichophyton mentagrophytes. Thus, lydimycin is useful alone or in combination with other antifungal or antibiotic agents to prevent the growth of, or reduce the number of, susceptible organisms present in various environments.